Photo: Getty
PresidentJoe Biden’s recent health relapse has raised some questions aboutCOVID-19rebound.
After firsttesting positive for the coronaviruson Thursday, July 21, Biden, 79, began aPaxlovidtreatment andstarted testing negativeagain on Tuesday evening. The White House later revealed that hetested positive againon Saturday in what has become known as a rebound case.
In astatementon Sunday, the president’s physician, Dr. Kevin C. O’Connor, noted that Biden “continues to feel well” while still testing positive. He will continue conducting business while remaining under “strict isolation.”
The Biden administration has previouslyrecommended the use of Paxlovid, of which more than 3 million courses have been administered in the United States since December, according to theDepartment of Health and Human Services.
As Biden continues to recover, here are some important facts to know about COVID-19 rebound.
What is COVID-19 rebound?
Back in May, the Centers for Disease Control and Prevention (CDC) releasedguidanceon COVID-19 rebound, which is described as “a recurrence of symptoms or a new positive viral test after having tested negative.”
Rebound cases have been reported in patients between two to eight days after their initial recovery, and symptoms continue to be mild in those who have completed Paxlovid treatment.
“Based on information from the case reports, COVID-19 rebound did not represent reinfection with SARS-CoV-2 or the development of resistance to Paxlovid,” the guidance added.
“There was no increased occurrence of hospitalization or death, and there was no evidence that the rebound in detectable viral RNA was the result of SARS-CoV-2 resistance to Paxlovid,” the report added.
Fabian Sommer/picture alliance via Getty Images
How common are COVID-19 rebound cases?
Although rebound cases have been reported to be rare, some medical experts say they’re more common than originally thought, according toThe Washington Post.
Catherine Bennett, a professor of epidemiology at Deakin University in Australia, told the outlet that rebound cases are “not rare, but uncommon,” as they’ve occurred with around 10 percent of people who’ve been treated with Paxlovid.
Never miss a story — sign up forPEOPLE’s free daily newsletterto stay up-to-date on the best of what PEOPLE has to offer, from juicy celebrity news to compelling human interest stories.
In a study published last month inClinical Infectious Diseases, researchers from the University of California San Diego School of Medicine found that rebound cases in Paxlovid users appeared to be due to insufficient exposure to the drug, meaning that higher dosages or longer treatment durations could be necessary pending further research.
Is COVID-19 rebound contagious?
Dr. Michael Charness of the Veterans Administration Medical Center in Boston toldCNNthat those who experience rebound COVID are “at risk of transmitting to other people, even though they’re outside what people accept as the usual window for being able to transmit.”
Charness previously worked with a team of researchers at Columbia University that found at least two instances of patients with COVID-19 rebound transmitting the infection to others, even before symptoms returned.
Andrew Harnik-Pool/Getty
“It’s certainly conceivable that there are other people out there who don’t have symptoms and still have a viral rebound,” Charness added.
Although transmission of infection during rebound cases has been reported, CDC notes that “it remains unknown whether the likelihood of transmission during rebound differs from the likelihood of transmission during the initial infection.”
What treatment do COVID-19 rebound cases require?
Those with rebound cases should continue to follow the CDC’sisolation guidelinesfor at least five days, after which they can end quarantine if symptoms are improving and they’ve gone 24 hours without a fever (and without the help of fever-reducing medication).
Patients should also continue to wear a mask for 10 days after rebound, CDC stated. If symptoms worsen, they are advised to see their doctor.
“There is currently no evidence that additional treatment is needed with Paxlovid or other anti-SARS-CoV-2 therapies in cases where COVID-19 rebound is suspected,” the CDC noted in their guidance while stressing that the drug is still “recommended for early-stage treatment of mild to moderate COVID-19 among persons at high risk for progression to severe disease.”
source: people.com
